A final list of drugs to be included in China's public health insurance scheme was released on January 18. A total of 111 drugs had been added to the catalogue, and that three drugs had been dropped.
Junshi Biosciences, a Chinese biopharmaceutical company, announced on January 18 that the country's medical products authorities had accepted a new drug application for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116) for the treatment of COVID-19.
On the evening of December 13, Fosun Pharma, the exclusive commercial partner of Chinese COVID-19 oral drug Azvudine, confirmed that the pills can soon be prescribed through online medical platforms.
At the HUAWEI CONNECT 2022, Ken Hu, Rotating and Acting Chairman of Huawei, delivered a keynote titled "Unleash Digital," where he talked about how the company is helping organizations make the most of cloud technology to leapfrog their developments.
Yunnan Baiyao Group, a Chinese medicine developer and manufacturer, announced on July 25 its signing of the "Comprehensive Cooperation Agreement on Artificial Intelligence Drug R&D," alongside Shenzhen-based tech giant Huawei.
The stock price of Yiling Pharmaceutical plunged after Wang Sicong, director of Wanda Group, reposted a video on Weibo that questioned whether the WHO had ever recommended the firm’s drug as Covid-19 treatment.
On Tuesday, Chinese 3D printing pharmaceutical company Triastek announced the completion of several hundred million yuan in a B+ round of financing.
Sinotau Pharmaceutical Group announced in a document on Thursday that it has completed a D+ round of financing worth 320 million yuan ($50.03 million). The funds raised are for clinical R&D of new radioactive drugs.
AI pharmaceutical company Galixir announced on Dec. 29 the completion of its latest two financing rounds, the Series A and Series A+, together worth tens of millions of dollars.